world1 outlet covering this

FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease

First publishedJul 1, 21:29 UTC

Last updatedJul 12, 12:32 UTC · 13m ago

↻

each logo = when that outlet publishedlast updated on Braven

Story signals

How strong is this topic?

High significance means broad impact or urgency. Source trust reflects the average authority of outlets covering the story.

Significance5.3

Weighted from impact, urgency, coverage breadth, and topic sensitivity.

Source trust10.0

Average reliability level of outlets included in this topic.

Outlets1

Independent sources contributing to this topic cluster.

More outlets usually means a more confirmed developing story.

The report

The U.S. Food and Drug Administration today issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients aged 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent β thalassemia (TDT).

Read the full report at FDA ↗

Related in the knowledge graph

organizationCasgevy organizationDrug Administration organizationFDA Approves First Gene organizationSCD organizationSickle Cell Disease. The organizationTherapy organizationVOCs organizationYoung Children

Sources (1)

Avg source rating 10.0/10

FDA10